Glicla-Natrapharm Dosage & Drug Information

Concise Prescribing Info Full Prescribing Info Contents Action Indications/Uses Dosage/Direction for Use Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Concise Prescribing Info

Contents

Gliclazide

Indications/Uses

Treatment of type 2 DM.

Click to view Glicla-Natrapharm detailed prescribing information

Dosage/Direction for Use

Initially 30 mg once daily. May be increased up to a max of 120 mg daily if necessary.

Click to view Glicla-Natrapharm detailed prescribing information

Administration

Should be taken with food.

Contraindications

Type 1 DM. Patients w/ ketoacidosis, severe infections, trauma or other severe conditions where drug is unlikely to control hyperglycemia. Severe hepatic & renal impairment. Porphyria. Pregnancy & lactation.

Click to view Glicla-Natrapharm detailed prescribing information

Special Precautions

Monitor blood glucose conc carefully in patients w/ renal impairment.

Click to view Glicla-Natrapharm detailed prescribing information

Use In Pregnancy & Lactation

Click to view Glicla-Natrapharm detailed prescribing information

Adverse Reactions

GI disturbances eg, nausea, vomiting, heartburn, anorexia, diarrhea & metallic taste; increased appetite, wt gain; skin rashes, pruritus, photosensitivity.

Click to view Glicla-Natrapharm detailed prescribing information

Storage

View Glicla-Natrapharm storage conditions for details to ensure optimal shelf-life.

Action

View Glicla-Natrapharm mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Antidiabetic Agents

ATC Classification

A10BB09 - gliclazide ; Belongs to the class of sulfonylureas. Used in the treatment of diabetes.

Regulatory Classification

Presentation/Packing

Form

Glicla-Natrapharm MR tab 30 mg

Packing/Price

15's;60's (P318.65/box)

Glicla-Natrapharm

gliclazide

Manufacturer:

Natrapharm

Distributor:

Natrapharm